Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 423.50M P/E - EPS this Y -6.50% Ern Qtrly Grth -
Income -94.05M Forward P/E -18.33 EPS next Y 49.70% 50D Avg Chg -1.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 33.00%
Dividend N/A Price/Book 40.24 EPS next 5Y - 52W High Chg -19.00%
Recommedations 1.70 Quick Ratio 0.75 Shares Outstanding 23.66M 52W Low Chg 106.00%
Insider Own 35.58% ROA -83.69% Shares Float 13.54M Beta 0.65
Inst Own 35.95% ROE - Shares Shorted/Prior 2.47M/2.43M Price 1.65
Gross Margin - Profit Margin - Avg. Volume 1,276,037 Target Price 37.20
Oper. Margin - Earnings Date Dec 20 Volume 1,001,706 Change -1.20%
About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Outlook Therapeutics, Inc. News
11/06/24 Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
10/17/24 Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment
09/16/24 Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
09/13/24 Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
09/04/24 Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
09/03/24 Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/15/24 Q3 2024 Outlook Therapeutics Inc Earnings Call
08/14/24 Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update
08/12/24 Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
08/09/24 Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now?
08/07/24 Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast
07/30/24 Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
07/08/24 Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
06/25/24 3 Undervalued Gems Set to Soar 1,000% by 2026
06/19/24 Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private equity firms own 31%
06/11/24 Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
05/28/24 Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
05/17/24 Q2 2024 Outlook Therapeutics Inc Earnings Call
05/15/24 Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
05/13/24 Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
OTLK Chatroom

User Image PaytiencePaysGreen Posted - 5 hours ago

$OTLK double bottom this week! Trend reversing. Good luck to all!

User Image GenerallyGentle Posted - 11 hours ago

$OTLK definition of insanity is going back to a price level multiple times where there is low/no volume and expecting to find new volume. LOL

User Image GenerallyGentle Posted - 11 hours ago

$OTLK I am telling you MMs you took the price too low. Broke the technical chart and you lost peoples interest. You wont find volume now. But hey .. what do I know. Maybe you are okay eating tuna salad sandwich for lunch everyday.

User Image Britbox Posted - 12 hours ago

$OTLK no news, no volume

User Image PaytiencePaysGreen Posted - 13 hours ago

$OTLK still low volume...drying up

User Image GenerallyGentle Posted - 17 hours ago

$OTLK to my friends, MCRB is getting ready to make some serious moves. added in yesterday. it will be a BO situation and Nestle is the buyer

User Image Britbox Posted - 18 hours ago

$OTLK had a dream it squeezed up to 3200% and the board was lit up like a Christmas tree. Btw, all my dreams eventually come true

User Image biostockhunter Posted - 1 day ago

$OTLK They could have the additional non dilutive funding already secured. Just waiting for N8 positive data then both will be announced together 🤞

User Image stock_master84 Posted - 1 day ago

$OTLK There is no market interest.

User Image GenerallyGentle Posted - 1 day ago

$OTLK volume dead zone below $5.20 .. just stalling for time now as the price vacillates from lower volume dead zone to upper volume dead zone

User Image Crazyhorse6 Posted - 1 day ago

$OTLK added, still very cheap!!

User Image Waldo_III Posted - 1 day ago

$OTLK same morning pattern day after day, straight up then free falls!

User Image PaytiencePaysGreen Posted - 1 day ago

$OTLK bought the dip! Anyone?

User Image stock_master84 Posted - 1 day ago

$OTLK The famous saying in biotechs pending data, the longer the wait, the scarier it gets. They are going to drag this further. Ask the question, they should know data by now at least the primary endpoint, why is there no run up? Why the price is declining instead? Why no partnership/licensing agreement? It is time to wake up, don’t let your ego burn you. Face reality, this is biotech!

User Image adayxs Posted - 1 day ago

$OTLK (June 15, 2022 Yea, this is only worth 121 mil. By Szilárd Kiss, MD)Today, more than 50% of patients with wet age-related macular degeneration (AMD) are treated off-label with repackaged intravenous bevacizumab (Avastin) that was formulated and packaged for oncologic use. https://www.modernretina.com/view/perspectives-on-intravenous-bevacizumab-repackaged-for-intravitreal-use

User Image PaytiencePaysGreen Posted - 2 days ago

$OTLK Dec timeline looks more likely now and make sense as enrolment just complete in Sep, recently

User Image Ang418 Posted - 2 days ago

$OTLK stock master not sure how to read you. There are some days when I think you’re really just waiting for the price to become lower to get in and there’s days where you almost make fun of people that bought the stock already. I do know one thing about you. I’m sure in high school somebody pulled your underwear right over head and gave you the worst wedgy imaginable.😂😂 you’re a very irritating person. Would love to see a picture of you so I can have a good laugh.

User Image GenerallyGentle Posted - 2 days ago

$OTLK below $5.20 volume tapers off into a dead zone. Not completely sure why you wanna revisit it again MMs. but hey you do you.

User Image GenerallyGentle Posted - 2 days ago

$OTLK just a reminder shorts ... your options are dilution, or bad trial data at this point to cover handsomely.

User Image PaytiencePaysGreen Posted - 2 days ago

$OTLK wide spread btw bid and ask. MMs playing trick to steal shares

User Image PaytiencePaysGreen Posted - 2 days ago

$OTLK xbi market still red. Low volume trending down does not mean anything

User Image GenerallyGentle Posted - 2 days ago

$OTLK Will shorts get bailed out this time with a new financing dilutive deal? Yes/No ?

User Image GenerallyGentle Posted - 2 days ago

$OTLK look at all that volume :P No one is interested in selling, or buying at these levels. Haha. dead zone. took it too low now and stuck because there will be no sellers here. now we sit and wait .......... and wait .... and wait

User Image Britbox Posted - 2 days ago

$OTLK

User Image Britbox Posted - 2 days ago

$OTLK out with the news already dammit!!!

User Image adayxs Posted - 2 days ago

$OTLK You absolutely do not want them to rush the trial. Do it correctly and get good complete data. I don't know what all the rush is anyway. This is most likely a hold to mid next year.

User Image stock_master84 Posted - 2 days ago

$OTLK Garbage stock

User Image opportoni Posted - 2 days ago

$OTLK Give us that data already

User Image Britbox Posted - 2 days ago

$OTLK the longer it’s low, the more I’ve accumulate, lowering my cost average and significantly increasing my eventual earnings.

User Image PaytiencePaysGreen Posted - 2 days ago

$OTLK pos really taking his time. Dec, it is, even though lightning fast enrollment, but turtle speed in the data.

Analyst Ratings
Chardan Capital Buy Aug 16, 24
HC Wainwright & Co. Buy Aug 15, 24
HC Wainwright & Co. Buy May 17, 24
BTIG Buy Mar 27, 24
HC Wainwright & Co. Buy Mar 25, 24
Chardan Capital Buy Feb 15, 24
Guggenheim Buy Jan 25, 24
Brookline Capital Buy Jan 25, 24
Ascendiant Capital Buy Dec 29, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dagnon Terry Chief Operations Off.. Chief Operations Officer Apr 20 Sell 1.135 520,000 590,200 653,058 04/21/23
Evanson Jeff Chief Commercial Off.. Chief Commercial Officer Jan 20 Sell 1.11 267,000 296,370 745,975 01/24/23
Evanson Jeff Chief Commercial Off.. Chief Commercial Officer Jan 17 Sell 1.26 164,155 206,835 1,012,975 01/19/23
HILZINGER KURT J Director Director Oct 04 Buy 1.26 111,203 140,116 473,117 10/05/22
Dagnon Terry Chief Operating Offi.. Chief Operating Officer Jun 21 Buy 1.05 10,000 10,500 1,173,058 06/23/22
TRENARY C RUSSELL III CEO and President CEO and President Jun 21 Buy 1.06 19,925 21,120 54,925 06/23/22
HILZINGER KURT J Director Director Mar 01 Buy 1.69 27,708 46,827 273,117 03/03/22
HILZINGER KURT J Director Director Feb 24 Buy 1.53 47,160 72,155 245,409 02/28/22
HILZINGER KURT J Director Director Feb 22 Buy 1.47 175,132 257,444 198,249 02/23/22